<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753504</url>
  </required_header>
  <id_info>
    <org_study_id>148HPS15001</org_study_id>
    <nct_id>NCT02753504</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519</brief_title>
  <official_title>A Dose-block Randomized, Double-blind, Placebo-controlled, Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety/tolerability and
      pharmacokinetics/pharmacodynamics of CKD-519
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Dose-block Randomized, Double-blind, Placebo-controlled, Multiple Dosing, Dose-escalation
      Phase I Clinical Trial to Investigate the Safety/Tolerability and
      Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult
      Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax,ss of CKD-519</measure>
    <time_frame>Day1: 0(predose)~24 Day3~Day13: 0(predose) Day14: 0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt,ss of CKD-519</measure>
    <time_frame>Day1: 0(predose)~24 Day3~Day13: 0(predose) Day14: 0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf,ss of CKD-519</measure>
    <time_frame>Day1: 0(predose)~24 Day3~Day13: 0(predose) Day14: 0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax,ss of CKD-519</measure>
    <time_frame>Day1: 0(predose)~24 Day3~Day13: 0(predose) Day14: 0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 of CKD-519</measure>
    <time_frame>Day1: 0(predose)~24 Day3~Day13: 0(predose) Day14: 0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin,ss of CKD-519</measure>
    <time_frame>Day1: 0(predose)~24 Day3~Day13: 0(predose) Day14: 0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cavg,ss of CKD-519</measure>
    <time_frame>Day1: 0(predose)~24 Day3~Day13: 0(predose) Day14: 0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLss/F of CKD-519</measure>
    <time_frame>Day1: 0(predose)~24 Day3~Day13: 0(predose) Day14: 0(predose)~168</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>accumulation ratio(D14/D1: Cmax, AUC0-t) of CKD-519</measure>
    <time_frame>Day1: 0(predose)~24 Day3~Day13: 0(predose) Day14: 0(predose)~168</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CETP activity of CKD-519</measure>
    <time_frame>Day1: 0(predose)~24 Day3~Day13: 0(predose) Day14: 0(predose)~168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CETP concentration of CKD-519</measure>
    <time_frame>Day1, 2, 6, 10, 14: 0(predose) Day15, 16, 17: Day14(24, 48, 72)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid parameter(HDL-c, LDL-c, Total Cholesterol, Triglyceride) of CKD-519</measure>
    <time_frame>Day1, 3, 7, 10, 12, 14: 0(predose) Day15, 16, 17, 21: Day14(24, 48, 72, 169)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid parameter(Apolipoprotein A-I, E, B) of CKD-519</measure>
    <time_frame>Day1, 8: 0(predose) Day15: Day14(24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT/QTc(QTcF, QTcB, QT, HR, RR, PR, QRS) of CKD-519</measure>
    <time_frame>Baseline(Day-1): 0~12 Day1: 0~24 Day14: 0~24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>CKD-519 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 50mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 100mg or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-519 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CKD-519 200mg or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-519</intervention_name>
    <arm_group_label>CKD-519 50mg</arm_group_label>
    <arm_group_label>CKD-519 100mg</arm_group_label>
    <arm_group_label>CKD-519 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>CKD-519 50mg</arm_group_label>
    <arm_group_label>CKD-519 100mg</arm_group_label>
    <arm_group_label>CKD-519 200mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 19 aged and 55 aged in healthy adult

          2. Body weight more than 55kg in male, 50kg in female

          3. Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)

          4. If female, must include more than one among the items

               -  The menopause(there is no natural menses for at least 2 years)

               -  Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or
                  other methods of infertility condition

          5. If men has sexual life with women of childbearing age, Necessarily he agrees that use
             condoms and do not sperm donation until two months during clinical trials and after
             the final dosage of investigational products

          6. Those who fully understand about this clinical trials after enough hearing, and then
             decided to join the clinical trials by themselves and to comply with the precautions
             written consent

        Exclusion Criteria:

          1. Have clinically significant disease that hepatobiliary system(severe hepatic
             impairment, etc), kidney(severe renal impairment, etc), nervous system, immune system,
             respiratory system, endocrine system, hemato-oncology disease, cardiovascular
             system(heart failure, etc) or mental illness, or a history of mental disease.

          2. Have a history of Toresades de pointes(TdP) or additional risk factors for Toresades
             de pointes(TdP). (Family history of long QT syndrome or sudden death, heart failure,
             hypokalemia, etc)

          3. Have a gastrointestinal disease history that can effect drug absorption(Crohn's
             disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)

          4. Hypersensitivity reaction or clinically significant hypersensitivity reaction in the
             history of drugs or additives.

          5. An impossible one who participates in clinical trial including screening tests(medical
             history taking, BP, 12-lead ECG, physical examination, blood&amp;urine laboratory test
             result) before 28 days the taking investigational Products.

          6. Defined by the following laboratory parameters

               -  AST, ALT&gt;1.25 upper limit of normal range

               -  Total bilirubin&gt;1.5 upper limit of normal range

               -  CPK&gt;1.5 upper limit of normal range

               -  eGFR(using by MDRD method)&lt;60mL/min/1.73m2

          7. Defined by the following 12-lead ECG

               -  HR&lt;40 or &gt;110bpm

               -  PR interval&gt;220ms or â‰¤110ms

               -  QRS interval&gt;120ms

               -  QTcF&lt;300ms or &gt;450ms

               -  Pathologic Q-waves (defined as &gt;40ms or depth&gt;0.5mV)

               -  Incomplete or complete bundle branch block

               -  Pre-excitation (e.g., Wolfe-Parkinson-White Syndrome)

               -  Atrial fibrillation/flutter

               -  Second- or third-degree atrioventricular (AV)block

               -  Investigator judges to be unfavorable for consistently accurate QT
                  measurements(e.g., indistinct QRS onset, low amplitude T wave, inverted or
                  terminally inverted T wave, merged T/U waves, indistinct T wave offset , or
                  prominent U wave that affects QT measurement)

          8. Sitting SBP&gt;150mmHg or &lt;90mmHg, sitting DBP&gt;100mmHg or &lt;50mmHg, after 5 minutes break.

          9. Drug abuse or have a history of drug abuse showes a positive for urine drug test.

         10. Pregnant or lactating women.

         11. A heavy caffeine consumer(caffeine&gt;5 cups/day), alcohol consumer(alcohol&gt;210g/week),
             or smoker(cigarette&gt;10 cigarettes/day)

         12. Subject takes ethical drug or herbal medicine within 14 days, OTC within 7 days before
             the beginning of study treatment but investigator determine that the taking drug
             affect this study or could affect the safety of subjects.

         13. Subject who takes inhibitor and inducers of drug metabolizing enzyme(Barbiturates
             etc.) within 30 days.

         14. Taking concomitant medications that prolong the QT/QTc interval within 14 days before
             the beginning of study treatment.

         15. Taking foods containing grapefruit within 7 days before the beginning of study
             treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days
             before the beginning of study treatment)

         16. Subject who treated with any investigational drugs within 90 days before the beginning
             of study treatment

         17. Previously donate whole blood within 60 days or component blood within 30 days.

         18. An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason.

         19. Positive for Serology test(Hepatitis B, Hepatitis C, HIV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Su Park, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

